Psychedelics started 2024 with a bang, and the innovative medicines are continuing to gain traction as the year progresses.
Following several transformative milestones in psychedelics, coupled with a surge in biotech investment, 2024 is set to see a profound shift for the sector as investors...
Beckley Psytech has confirmed it has received a strategic investment of USD$50 million from atai Life Sciences to accelerate the development of Beckley Psytech’s two clinical-stage,...
Psychedelic Medicine Investment Fund Negev Capital is aiming to innovate mental healthcare in Europe by providing funding to companies on the cutting edge of psychedelic research.
LongeVC has invested in psychedelics startup Freedom Biosciences which is pioneering the use of ketamine and other compounds in next-generation treatments.
Psychedelics venture studio Nucleus has raised USD$135,000 from investors through its Wefunder campaign.
BetterLife Pharma has secured investment from Negev Capital and further European investors that will go towards working capital purposes and the advancement of pre-clinical and clinical...
Clarify Pharma has acquired shares to the value of £250,000 in each of Atai Life Sciences and Compass Pathways as part of its investment strategy.